The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.
>Tofa(56%) vs. pbo(29.4%)-significant improvement in AS
Rituximab in ILD (all observational)
#1053 ➡️ 47 with CTD-ILD: overall imp
- The future is bright with many trainees producing great research per Dr
Dr. Jack Cush interviews Dr. Ken Saag about the benefits of adding mycophenolate to your pegloticase regimen in refractory gout patients.
Everyone hates steroids, right?
GUSTO trial: IVMP 500m